Global healthcare company
UK's Theramex sees no impact to HRT products supply after CMA probe: Theramex said on Friday it was considering concerns raised by Britain's competition ...
reuters.com/world/uk/uks-theramex-sees-no-impact-hrt-products-supply-after-cma-probe-2024-04-05/
Supporting access to critical medicines: Viatris' commitment in Europe: Europe’s Critical Medicines Alliance launches today. This is an occasion to reflect on ...
euractiv.com/section/health-consumers/opinion/supporting-access-to-critical-medicines-viatris-commitment-in-europe/
These stocks are too cheap to ignore: Experts recommend these undervalued stocks: These 5 stocks are simply too cheap to ignore. Which undervalued stocks ...
boerse-online.de/nachrichten/aktien/diese-aktien-sind-zu-guenstig-um-sie-zu-ignorieren-experten-empfehlen-diese-unterbewerteten-aktien-20354818.html
Miller Value Partners Income Strategy Q1 2024 Letter: The Miller Income Strategy returned 11.69% (net of fees) in the first calendar quarter of 2024 ...
seekingalpha.com/article/4683311-miller-value-partners-income-strategy-q1-2024-letter
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent: Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their ...
reuters.com/business/healthcare-pharmaceuticals/teva-viatris-win-new-chance-challenge-jj-schizophrenia-drug-patent-2024-04-01/
Viatris generic hypertension drug does not violate J&J patents, US court says: Generic drugmaker Viatris has convinced a federal judge in West Virginia that its ...
reuters.com/legal/litigation/viatris-generic-hypertension-drug-does-not-violate-jj-patents-us-court-says-2024-03-15/
Viatris Stock Is Still Worth Buying: Viatris stock shows promising growth potential with two new drugs ready for commercialization. See why we recommend a buy ...
seekingalpha.com/article/4681271-viatris-stock-is-still-worth-buying
Paid articlePaid
Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued: VTRS's focus on debt reduction and strategic progress signals a promising future ...
seekingalpha.com/article/4675464-vtrs-stock-up-25-percent-4-percent-yielding-viatris-up-to-60-percent-undervalued
Paid articlePaid Viatris forecasts strong 2024 sales on higher demand for branded drugs: Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday ...
reuters.com/business/healthcare-pharmaceuticals/viatris-forecasts-strong-2024-sales-higher-demand-branded-drugs-2024-02-28/
Expansion: New OTC player is forming: Cooper Consumer Health from France is expanding. The group is not only taking over the former Madaus OTC brands from ...
lebensmittelzeitung.net/industrie/nachrichten/expansion-neuer-otc-player-formiert-sich-176167
Paid articlePaid
Regeneron (REGN) Stock Gains After Eye-Drug Patent Victory Over Viatris (VTRS): Regeneron Pharmaceuticals Inc. rose the most since August after a court ruled ...
bloomberg.com/news/articles/2023-12-27/regeneron-gains-after-eye-drug-patent-victory-over-viatris
Drugmaker Viatris appoints Theodora Mistras as CFO: Global healthcare company Viatris (VTRS.O) on Friday appointed Theodora Mistras as its chief financial ...
reuters.com/business/healthcare-pharmaceuticals/drugmaker-viatris-appoints-theodora-mistras-cfo-2023-12-15/
Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma: Viatris stock has been on the rise, up over 20% in the past month ...
seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma
Paid articlePaidQuick Glance: Viatris: Potentially Divisive Pharma Investment
- Viatris stock has seen a >20% increase recently, following the 2020 merger between Pfizer's Upjohn division and Mylan.
- Long-term shareholders are down ~25%, but Viatris' dividend of $0.12 per quarter or $0.48 per annum provides ~4% annual yield.
- Around 64% of Viatris' 2023 revenues will come from established brands, including patent-expired drugs, with 32% from generics and 4% from complex generics (Gx).
- Viatris markets and sells over 1,400 approved molecules, manufactured at 40 global sites.
Regeneron: Important achievement - Stock on the hunt for records: On Wednesday, Regeneron Pharmaceuticals shares rose to a new record high during trading.
deraktionaer.de/artikel/pharma-biotech/regeneron-wichtiger-erfolg-aktie-auf-rekordjagd-20346591.html
Why the Cheapest Stock in the S&P 500 Is No Bargain: Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division ...
barrons.com/articles/viatris-pharmaceuticals-biosimilars-epipen-mylan-961b6509
Paid articlePaid Drugmaker Viatris appoints Theodora Mistras as CFO: Global healthcare company Viatris (VTRS.O) on Friday appointed Theodora Mistras as its chief financial ...
reut.rs/3RIc3TO
8 Tax-Loss Sell Alerts For December: Investors should consider tax-loss selling before December ends to offset capital gains. Check out 8 firms to consider ...
seekingalpha.com/article/4657463-8-tax-loss-sell-alerts-for-december
Paid articlePaid Viatris US court win reopens path to generic of J&J hypertension drug: A U.S. appeals court on Monday gave Viatris' (VTRS.O) Mylan Pharmaceuticals another chance ...
reuters.com/legal/litigation/viatris-us-court-win-reopens-path-generic-jj-hypertension-drug-2023-11-06/
Viatris core profit beats on generic drugs strength: Viatris (VTRS.O) beat Wall Street estimates for third-quarter core profit on Tuesday ...
reuters.com/business/healthcare-pharmaceuticals/viatris-core-profit-beats-generic-drugs-strength-2023-11-07/
Drugmaker Viatris to divest some businesses for $3.6 bln: Drugmaker Viatris (VTRS.O) said on Sunday it had reached agreements to divest some of its businesses ...
reuters.com/business/healthcare-pharmaceuticals/drugmaker-viatris-divest-some-its-businesses-2023-10-01/
Viatris to sell India women health care, API businesses for $1.2 billion: API business in pharma: IQuest Enterprises has a slew of investments in the ...
business-standard.com/health/viatris-sells-api-and-women-s-healthcare-business-in-india-for-1-2-bn-123100200845_1.html
Viatris, the global pharmaceutical company headquartered in Cecil, announced Sunday it plans to divest multiple segments of its business for $6.94 billion. Show more
#VIP Inds promoters explore stake sale | Viatris sells 2 units in #India for $1.2 bn | Rocky #rupee drives NSE volumes to record high
Read today's Mint ... Show more epaper.livemint.com
IQuest Enterprises inks pact to acquire Viatris’ Indian API operations: Prasad has been a serial entrepreneur having developed significant businesses (Matrix ...
financialexpress.com/business/industry-iquest-enterprises-inks-pact-to-acquire-viatris-indian-api-operations-3260663/
Biocon may list biosimilars business by 2025 first half - CEO: Indian biopharmaceutical company Biocon Ltd (BION.NS) is planning to list its biosimilars business ...
reuters.com/markets/deals/biocon-may-list-biosimilars-business-by-2025-first-half-ceo-2023-08-11/
Quick Glance: Biocon to List Biosimilars Business by 2025 - CEO
- Biocon Biologics, a subsidiary of Biocon Ltd, focuses on manufacturing biosimilars in the United States and Europe.
- The biologics business may be listed on the stock market after the second half of 2024 and is expected to take place in the first half of 2025.
- Biocon acquired the biosimilar business of a US-based company last year.
- Revenue in the biosimilars business more than doubled to 20.15 billion Indian rupees in the last quarter.
Viatris beats second-quarter revenue estimates, says divestiture plans on track: Viatris Inc (VTRS.O) beat Wall Street estimates for second-quarter revenue on ...
reuters.com/business/healthcare-pharmaceuticals/viatris-beats-second-quarter-revenue-estimates-says-divestiture-plans-track-2023-08-07/
On track to integrate major part of Viatris’ acquired biosimilars business this fiscal: Kiran Mazumdar-Shaw
financialexpress.com/business/industry/on-track-to-integrate-major-part-of-viatris-acquired-biosimilars-business-this-fiscal-kiran-mazumdar-shaw/3227965/
Biocon Biologics ahead of plan in integrating biosimilar biz of Viatris: BBL is actively working on raising funds from private equity investors to retire part of ...
business-standard.com/companies/news/biocon-biologics-ahead-of-plan-in-integrating-biosimilar-biz-of-viatris-123081100679_1.html
Biocon IPO after integration of Viatris market: MD & CEO Shreehas Tambe: 'From our perspective, we have operated with a high band and a lower band model'
business-standard.com/companies/interviews/we-are-seeing-huge-demand-for-insulin-products-biocon-biologics-md-ceo-123052400868_1.html
Viatris, Organon, and 6 Other Defensive Healthcare Plays as Healthcare Stocks Stumble
barrons.com/articles/viatris-organon-defensive-plays-healthcare-stocks-7055d2ab
Paid articlePaid
Russia cut off by Viagra's producer, scrambling to make erection pills: Russia said on Wednesday that 36 local companies had the "technological possibility" to ...
businessinsider.com/russia-cut-off-by-viagras-producer-scrambling-make-erection-pills-2023-2
Paid articlePaid
Viatris deal-related expenses drag Biocons Q3 net into Rs 42 cr loss: This even as revenues rise 36 and Ebitda is up 35
business-standard.com/article/companies/viatris-deal-related-expenses-drag-biocon-s-net-profit-in-december-quarter-123021402110_1.html
Have to keep R&D spends at 12% of revenue: Biocons Kiran Mazumdar-Shaw: Its a high growth phase for us in Biocon Biologics We crossed the Rs 1500crore mark in ...
business-standard.com/article/companies/want-to-keep-r-d-at-12-of-topline-level-biocon-s-kiran-mazumdar-shaw-123021501733_1.html
Paid articlePaid Viatris, MedAccess and TB Alliance ink agreement to reduce price of medicine for treating multidrug-resistant tuberculosis
financialexpress.com/healthcare/news-healthcare/viatris-medaccess-and-tb-alliance-inks-agreement-to-reduce-price-of-medicine-for-treating-multidrug-resistant-tuberculosis/2919486/
Goldman Sachs' inflation picks — 10 stocks to buy if prices are peaking: Investors may start thinking about positioning for a new economic environment after the ...
cnbc.com/2022/12/13/goldmans-10-companies-to-buy-if-prices-are-peaking.html
Paid articlePaid Happy New Year! 5 Healthcare Stocks to Watch for 2023: By Josh Nathan-KazisBarron'sTranslation: Laura Markus 12/22/2022
deraktionaer.de/artikel/pharma-biotech/gesundes-neues-jahr-5-healthcare-aktien-fuer-2023-20323355.html
Viatris executive charged with insider trading that yielded $8 million in gains
post-gazette.com/business/healthcare-business/2022/11/11/viatris-executive-charged-insider-trading-8-million-mylan/stories/202211110119
Free health screening for aged 40 and above: Viatris Malaysia and the Malaysian Medical Association (MMA) will jointly organise a free health screening campaign ...
malaysiakini.com/announcement/647226
JPMorgan downgrades Teva as generic medication business struggles: Teva Pharmaceutical is hard to like as it continues to be weighed down by underperformance in ...
cnbc.com/2022/11/14/jpmorgan-downgrades-teva-as-generic-medication-business-struggles.html
Paid articlePaid ALTY and Viatris Collaborate To Help Improve Bone Health Awareness: ALTY, one of Malaysia’s first and only full-fledged orthopaedic hospitals has been placing ...
malaysiakini.com/announcement/646419
Pittsburgh pharmaceutical company making its move into ophthalmology field
post-gazette.com/business/healthcare-business/2022/11/07/viatris-mylan-opthamology-acquisition-oyster-point-famy-life-pharmaceutical/stories/202211070072
Finding yield in health care stocks during the market storm: In a rising interest rate environment, some parts of the sector may be poised for even better ...
cnbc.com/2022/09/23/finding-yield-in-health-care-stocks-during-the-market-storm.html
Paid articlePaid
Protecting patients’ access to affordable medicines as inflation bites: Presented by Viatris
politico.eu/event/protecting-patients-access-to-affordable-medicines-as-inflation-bites/
Protecting patients’ access to affordable medicines as inflation bites: Presented by Viatris
politico.eu/event/protecting-patients-access-to-affordable-medicines-as-inflation-bites/
Protecting patients’ access to affordable medicines as inflation bites: Presented by Viatris
politico.eu/event/protecting-patients-access-to-affordable-medicines-as-inflation-bites/
Flu season 2022/2023: More and more flu vaccines are coming to pharmacies: The pharmaceutical company Sanofi has started shipping the influenza vaccines ...
pharmazeutische-zeitung.de/immer-mehr-grippeimpfstoffe-kommen-in-die-apotheken-135206/
Median pay for executives at the largest companies surged last year. A few shareholders are crying foul.
post-gazette.com/business/bop/2022/07/04/executive-salaries-say-on-pay-shareholder-proxy-resolution-vote-compensation-packages-pay-ratio-fortunate-50/stories/202207030053
Flu season 2022/2023: First flu vaccines are coming to pharmacies: Viatris has shipped the first batches of its quadrivalent seasonal flu vaccines to pharmacies ...
pharmazeutische-zeitung.de/erste-grippeimpfstoffe-kommen-in-die-apotheken-134939/
Analysis: M&A deal value in healthcare and pharma hits record high in Jan-June | VCCircle
vccircle.com/analysis-m-a-deal-value-in-healthcare-and-pharma-hits-record-high-in-jan-june
3 Strong Dividend Stocks to Buy in June: Investors can expect recurring income from these stocks.
fool.de/2022/06/14/3-starke-dividendenaktien-die-im-juni-ein-kauf-sind/
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics